Investor Relations


Nanōmix Corporation, Inc. (OTCQB: NNMX)

Nanōmix is the leader in the development of mobile, affordable point-of-care diagnostics, with a Hand-held platform and assays that provide rapid, accurate, quantitative information for use in settings where time-to-diagnosis is critical to clinical decision making and improved patient care.

Nanōmix, Inc. completed a reverse merger transaction with Boston Therapeutics Inc. on June 4, 2021, becoming Nanōmix Corporation. Nanōmix announced the completion of its name change from Nanomix, Inc. to Nanomix Corporation and its ticker symbol from “BTHE” to “NNMX”. The Company’s common shares begin trading on the OTC Market under the NNMX ticker symbol as of the opening of the Market on November 15, 2021.

Investor Relations

David Ludvigson
President, CEO
5900 Hollis Street
Suite P
Emeryville, CA 94608
(510) 428-5300

Stock Quote